These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 20831661)

  • 1. Decision modelling of economic evaluation of intervention programme of breast cancer.
    Chang JC; Chen TH; Duffy SW; Yen AM; Chen SL
    J Eval Clin Pract; 2010 Dec; 16(6):1282-8. PubMed ID: 20831661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
    Naeim A; Keeler EB
    Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
    Karnon J
    Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
    Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
    Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation.
    Haines TP; Sinnamon P; Wetzig NG; Lehman M; Walpole E; Pratt T; Smith A
    Breast Cancer Res Treat; 2010 Nov; 124(1):163-75. PubMed ID: 20734132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological issues in the economic analysis of cancer treatments.
    Tappenden P; Chilcott J; Ward S; Eggington S; Hind D; Hummel S
    Eur J Cancer; 2006 Nov; 42(17):2867-75. PubMed ID: 17023160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presenting results of probabilistic sensitivity analysis: the incremental benefit curve.
    Bala MV; Zarkin GA; Mauskopf J
    Health Econ; 2008 Mar; 17(3):435-40. PubMed ID: 17694580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing reduced antibiotic use for pediatric acute otitis media.
    Meropol SB
    Pediatrics; 2008 Apr; 121(4):669-73. PubMed ID: 18381529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
    Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
    Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a surveillance programme for women with a family history of breast cancer.
    Reis MM; Tavakoli M; Dewar J; Goudie D; Cook A; McLeish L; Young D; Kenyon J; Steel M
    J Med Genet; 2009 May; 46(5):319-23. PubMed ID: 19279022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
    Hillner BE; Smith TJ
    N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer.
    Hagemann AR; Zighelboim I; Odibo AO; Rader JS; Mutch DG; Powell MA
    Breast J; 2011; 17(1):103-5. PubMed ID: 21155918
    [No Abstract]   [Full Text] [Related]  

  • 20. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis.
    Marino P; Roché H; Moatti JP;
    Am J Clin Oncol; 2008 Apr; 31(2):117-24. PubMed ID: 18391594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.